Primarily caused by exposure to asbestos, mesothelioma is a typical occupational disease. The latency of mesothelioma is as long as 20-40 years, and the cancer initially progresses mainly along the surfaces of pleura or peritoneum without forming masses. As symptoms do not develop until late stages, it has been challenging to diagnose this disease in its early stages and to carry out complete surgical removal. In responding to Japan's asbestos crisis in the mid-2000s, we have developed and improved ERC/MSLN-based serum and radiological markers and pioneered the use of an N-ERC ELISA kit for screening populations at risk for asbestos exposure. In the present article, we review our research toward early diagnosis of asbestos-related mesothelioma before symptoms develop and share our clinical experience of screening, diagnosing and monitoring of this disease. This paper is dedicated to the author (Dr Okio Hino) to commemorate the honor bestowed upon him as the recipient of the Mataro Nagayo Prize in 2018.
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Median survival time after diagnosis is 12 months. 5 In this paper, we present our research on the ERC gene, the ERCbased serum biomarker (N-terminal ERC ELISA system) development, its clinical application in the process of screening and early diagnosis of mesothelioma in humans, and our research regarding pinpointing the location of mesothelioma tumors and treating the cancer by intratumoral injection of an anti-C-terminal ERC mAb in an animal model. Figure 1 shows our methodology considering early diagnosis of mesothelioma from a high-risk population with exposure to asbestos and leading to effective treatment in the future.
| RE S E ARCH HIS TORY AND RE SULTS

| Brief history of research on the ERC/MSLN gene and its products
The ERC gene, originally discovered as the Erc (expressed in renal carcinoma) gene in the study of the Eker (Tsc2 mutant) rat model, 6 is the name given to its human homolog gene, which was later identified as the MSLN gene. 7 (The Eker rat is a rat model that is predisposed to develop hereditary renal carcinomas as a result of two hit mutations of the tumor suppressor gene, Tsc2. 8 The Eker rat strain was originally developed by R. Eker, a Norwegian pathologist. Dr
Knudson later introduced the Eker rat to the USA for hereditary cancer studies and maintained the mutation by breeding the rats on a normal Long-Evans strain background.
)
In the study of Eker rat renal carcinogenesis, Hino et al 6 found that the following four genes were highly involved in renal carcinogenesis: the third component of complement (C3) gene, the fosrelated antigen 1 (fra-1) gene, the calpactin I heavy-chain (annexin II) gene, and an unknown gene, which was later named the Erc gene. 15 Although the number of patients enrolled was small, the 7-20 ELISA system was clinically proven useful for precise diagnosis of the epithelioid type of pleural mesothelioma. 
| N-ERC as diagnostic marker: Large-scale screening of construction workers for early diagnosis of asbestos-related mesothelioma by N-ERC ELISA in Japan
A 5-year large-scale screening of Japanese construction workers who were or had been at risk of asbestos exposure was started in Hirohash et al 16 reported that, overall, 62 participants were ultimately identified as the "high-risk" population and referred to have further assessment. "High-risk" was defined as the following:
(i) HAMA not detected; (ii) age ≥35 years; and (iii) detection of abnormal values (>8.0 ng/mL) of N-ERC on more than two occasions during the annual assessments.
The study showed that: (i) mean N-ERC level of the high-risk population was similar to that of mesothelioma patients; and (ii) for the high-risk population, annual N-ERC level increased significantly at ~2.0 points annually. 16 During the 5-year study period, two patients in the high-risk population developed mesothelioma, and two other patients developed lung and appendiceal cancer. Others in the high-risk population were encouraged to have annual check-ups.
| N-ERC Index as a monitoring and prognostic marker for pleural mesothelioma
Between June 2005 and June 2010, 26 inoperable patients with histologically confirmed pleural mesothelioma (21 epithelial type, 4 sarcomatoid type, and 1 biphasic type) were recruited for chemotherapy treatment at Juntendo University Hospital of Japan. 17 The most frequently used regimen was pemetrexed + cisplatin. Overall response rate was 19.2% with five partial responses (PR), 10 patients with stable disease (SD) and 11 patients with progressive disease (PD).
Blood samples were measured for N-ERC levels twice using the 
| D ISCUSS I ON
Usually diagnosed at late stages, mesothelioma is rapidly progressive and invariably fatal. Chemotherapy has only a modest impact on survival-adding approximately 2-3 months to overall survival and reducing time to progression. 20 Currently, the most effective treatment in practice is removal of the tumor at early stages. Biomarker development, therefore, is critical for high-risk population screening and early diagnosis of asbestos-mesothelioma.
Since the discovery of the ERC/MSLN gene in 1994, we have Table 1 shows representative studies of these biomarkers and their results.
Mesothelin is one of the most extensively studied mesothelioma biomarkers and is the only blood-based biomarker approved by FDA in mesothelioma diagnosis. However, studies showed that although it is characterized by good specificity, it has low sensitivity, especially for non-epithelioid mesothelioma. Serum HNGB1 can be considered a prognostic marker, rather than a diagnostic marker, for MPM. Regarding fibulin-3, studies do not show consistent results. However, some studies are investigating the hypothesis that fibulin-3 may be responsible for the malignant transformation of mesothelial cells after exposure to asbestos and/or asbestos-like fibers. 24 Concerning OPN, the results obtained by Pass et al (see Table 1 ) were not confirmed by other F I G U R E 4 N-ERC can be used as a diagnostic marker for early diagnosis of mesothelioma before symptoms develop, and as a prognostic marker to monitor the effectiveness of treatments. A, Time frame when N-ERC can be used as a diagnostic marker for early diagnosis. B, Time frame when N-ERC can be used as a prognostic marker for monitoring the effectiveness of treatments research groups. 25 Whether OPN is a biomarker of mesothelioma is still under discussion.
Other recent studies toward early diagnosis of mesothelioma include research regarding the antibodies YP218 and YP223 and histopathological marker development based on SKM9-2. In 2015, Zhang et al 26 reported the discovery of a new group of high-affinity mAb recognizing non-overlapping epitopes on mesothelin. One pair of antibodies (YP218 and YP223) was reported to be suitable to detect soluble mesothelin in a sandwich ELISA with high sensitivity, bringing the detection limit of soluble mesothelin lower than that of MESOMARK (Fujirebio Diagnostics Inc., Malvern, PA, USA). 26 As for histopathological marker development, it was reported in 2017 that SKM9-2, a mAb against sialylated HEG1, was effective in detecting sarcomatoid (64%) and desmoplastic (50%) pleural mesothelioma (2017).
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Although mesothelioma is considered to be primarily caused by exposure to asbestos, the mechanism of mesothelioma is not fully elucidated. Our ERC/MSLN-based research has been conducted toward early diagnosis and treatment of mesothelioma. To further improve the sensitivity of our biomarkers and to develop treatment methods, differentiation in terms of expressed glycoproteins between normal mesothelial cells and mesothelioma cells is currently being studied in our laboratory.
With a long latency, asbestos-related mesothelioma is expected to peak in the next decade across developed countries, and the world will see a significant increase in the incidence of mesothelioma in developing countries in the coming decades. Japan has experienced a significant increase in mesothelioma incidence from the mid-2000s.
In response to this growing crisis, the author (Okio Hino) was instrumental in opening an outpatient clinic for asbestosis/mesothelioma; he also identified ERC as a novel serum marker for mesothelioma.
We have developed our Juntendo (Tokyo) Model-preliminary N-ERC serum biomarker tests for a population with exposure to asbestos and secondary tests by biomarkers combined with PET-CT and biopsy for subjects of abnormal N-ERC value (cut-off value of 8 ng/ mL)-to achieve early diagnosis and early treatment of asbestosrelated mesothelioma. By implementing our Juntendo (Tokyo) Model across Japan, more patients could be found at early stages before symptoms develop, therefore early treatment would be possible.
As the winner of the Mataro Nagayo Prize in 2018, the author (Okio Hino) appreciates the opportunity to contribute to the global society by sharing our learned knowledge with other countries experiencing increased incidence of asbestos-related mesothelioma.
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HMGB1
Tabata et al (2013) studied 106 subjects with a history of asbestos exposure. Of them, 61 had confirmed MPM, 26 had pleural plaques and/or asbestosis, and 19 had no asbestos-related lesions despite being exposed to asbestos 29 At the optimal cut-off value of 9.0 ng/mL, diagnostic sensitivity was 34.4% and specificity was 100% Serum HMGB1 concentrations of patients with MPM were significantly higher (median: 6.7, IQR: 4.8-11.0 ng/mL) than those of patients with benign asbestos-related diseases (asbestosis or pleural plaques) and healthy individuals (median: 5.4, IQR: 4.0-6.7 ng/mL) 29 Fibulin-3 Pass et al (2012) studied a sample of 92 mesothelioma patients and 290 controls (formerly exposed to asbestos, subjects with benign and malignant pleural effusions not from mesothelioma, other tumors, and unexposed healthy subjects) 30 Pass et al showed a high diagnostic accuracy of fibulin-3 (AUC = 0.99) with sensitivity of 97% and specificity of 95% 30 Creaney et al (2015) studied a cohort of 153 patients (82 of whom had mesothelioma) 31 Creaney et al reported a sensitivity of 22% and a specificity of 95% for plasma fibulin-3 (cut-off: 52 ng/mL, AUC = 0.671) 
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